Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Multi-Dose PK Phase - Daily Group Clear all
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

NCT00652626
View directory record Official record
Conditions
MDS, AML, Solid Tumors, Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Berkeley, California • Hialeah, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

NCT02372084
View directory record Official record
Conditions
Hepatic Impairment
Interventions
osilodrostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 9:15 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Characterization of Doxycycline Pharmacokinetics and Adherence

NCT07755618
View directory record Official record
Conditions
Sexually Transmitted Infection
Interventions
Single-Dose PK Phase - DR Group, Single-Dose PK Phase - IR Group, Multi-Dose PK Phase - Daily Group, Multi-Dose PK Phase - Intermittent Group
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Pioglitazone
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 19, 2026, 9:15 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

NCT01835197
View directory record Official record
Conditions
Healthy
Interventions
PF-04965842, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 19, 2026, 9:15 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

NCT05437029
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin 3.0, Q-Griffithsin 6.0
Drug
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing

NCT01669083
View directory record Official record
Conditions
Embryo Transfer
Interventions
GSK557296 10 mg, GSK557296 150 mg, GSK557296 dose 3, GSK557296 dose 4
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

NCT02070939
View directory record Official record
Conditions
Healthy
Interventions
PF-06260414, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel

NCT01687205
View directory record Official record
Conditions
Pharmacokinetics of 1% Tenofovir Gel Following Coitus, Pharmacodynamics of 1% Tenofovir Gel Following Coitus
Interventions
1% Tenofovir Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 46 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients

NCT01915576
View directory record Official record
Conditions
Neoplasms
Interventions
BAY1125976
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Santa Monica, California • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

NCT05043766
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF614, Naltrexone Hydrochloride, OxyContin
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 2 Interventional

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

NCT06679829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Melphalan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824
View directory record Official record
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

NCT05966324
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

NCT05162053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
vicagrel Capsules, Clopidogrel Tablets
Drug
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02256475
View directory record Official record
Conditions
Tourette Syndrome
Interventions
NBI-98854
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
San Diego, California • Kissimmee, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 19, 2026, 9:15 PM EDT